OncoGynecologyNews.net

OncoGynecology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Search results for "Keytruda"

The phase 3 KEYNOTE-522 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with chemotherapy has met one of the dual-primary endpoints of pathological complete respon ...


As part of an ongoing phase Ib/II study ( NCT02501096 ) in patients with selected solid tumors, Lenvatinib [ Lenvima ] ( 20 mg PO [ per os ] QD [ once a day ] ) + Pembrolizumab [ Keytruda ] ( 200 mg I ...